CytRx Corporation (CYTR)
(Delayed Data from NSDQ)
$0.51 USD
-0.02 (-3.66%)
Updated May 3, 2019 04:00 PM ET
After-Market: $0.52 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
LadRx Corporation [CYTR]
Reports for Purchase
Showing records 1 - 20 ( 99 total )
Company: LadRx Corporation
Industry: Medical - Biomedical and Genetics
Company: LadRx Corporation
Industry: Medical - Biomedical and Genetics
Company: LadRx Corporation
Industry: Medical - Biomedical and Genetics
Arimoclomol Edges Closer to Potential Approval; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: LadRx Corporation
Industry: Medical - Biomedical and Genetics
Preclinical Development Phase Concludes; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: LadRx Corporation
Industry: Medical - Biomedical and Genetics
3Q18 Financial Results Reported; Cash Burn Rapidly Declining; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: LadRx Corporation
Industry: Medical - Biomedical and Genetics
2Q18 Financial Results Reported; Looking Ahead to Potential LADR Partnership; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: LadRx Corporation
Industry: Medical - Biomedical and Genetics
Provisional Patent Application Filed for Companion Diagnostic; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: LadRx Corporation
Industry: Medical - Biomedical and Genetics
Centurion BioPharma Formed to Unlock Potential of LADR- Pipeline; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: LadRx Corporation
Industry: Medical - Biomedical and Genetics
1Q 2018 Financial Results Reported; Cash Replenished; Reiterate Buy and Raising Target to $4.50
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: LadRx Corporation
Industry: Medical - Biomedical and Genetics
A Leaner, Meaner CytRx; Assuming Coverage at Buy and $4 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: LadRx Corporation
Industry: Medical - Biomedical and Genetics
Clarity on Regulatory Pathway Rekindles Aldox Value Proposition
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: LadRx Corporation
Industry: Medical - Biomedical and Genetics
Company: LadRx Corporation
Industry: Medical - Biomedical and Genetics
Pivotal Phase 3 Sarcoma Data Expected this Quarter
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: LadRx Corporation
Industry: Medical - Biomedical and Genetics
Company: LadRx Corporation
Industry: Medical - Biomedical and Genetics
Interim Phase 1b Data Highlight Aldox Safety and Chemo Add-on Potential
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: FEIN A
Company: LadRx Corporation
Industry: Medical - Biomedical and Genetics
4Q14 Update: Sarcoma Phase 3 Remains on Track, While Company Advances New Aldox Indications
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: FEIN A
Company: LadRx Corporation
Industry: Medical - Biomedical and Genetics
Dropping Coverage
Provider: Roth Capital Partners, Inc.
Company: LadRx Corporation
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: LadRx Corporation
Industry: Medical - Biomedical and Genetics
Positive Data and Program Expansions for Aldoxorubicin; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: LadRx Corporation
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.